CD5+MYC+ predicts worse prognosis in diffuse large B-cell lymphoma

Abstract

The dual expression of CD5 and MYC protein (DECM) on B-lymphocytes may arise at a specific stage of de novo diffuse large B-cell lymphoma (DLBCL). This study retrospectively reviewed 210 patients with de novo DLBCL at the Affiliated Hospital of Jiangnan University between 2006 and 2017. DECM was significantly correlated with a worse prognosis than that in either the CD5⁺ or MYC⁺ or CD5^-MYC^- patients. Furthermore, patients with DECM showed a similar outcome to MYC⁺BCL2⁺ lymphoma patients who have extremely poor survival rates. Multivariate analysis demonstrated that DECM was a significant independent predictor for overall survival (P < .0001) and progression-free survival (P < .0001) in DLBCL. DLBCL patients with DECM showed significantly inferior clinical outcomes compared to the CD5⁺, MYC⁺ or CD5^-MYC^- patients. Combinational therapeutic modalities might be a candidate approach to improve the prognosis of these patients.

Keywords: CD5; Diffuse large B-cell lymphoma; MYC; Prognosis; Survival.